Table 3 Factors associated with completing ⩾4 cycles in patients who started chemotherapy
From: Treatment decisions and survival for people with small-cell lung cancer
Total N =8768 a | % | Received ⩾4 cycles N =5540 (63%) | % | OR for completing ⩾4 cycles | 95% CI | Adjusted OR b | 95% CI | |
|---|---|---|---|---|---|---|---|---|
Sex | ||||||||
Female | 4166 | 47.5 | 2641 | 63.4 | 1.00 | 1.00 | ||
Male | 4602 | 52.5 | 2899 | 63.0 | 0.98 | 0.90–1.07 | 0.99 | 0.91–1.09 |
Age group | ||||||||
<55 | 895 | 10.2 | 618 | 69.1 | 1.41 | 1.19–1.68 | 1.29 | 1.07–1.54 |
55–59 | 1106 | 12.6 | 755 | 68.3 | 1.36 | 1.16–1.60 | 1.26 | 1.07–1.49 |
60–64 | 1620 | 18.5 | 1058 | 65.3 | 1.19 | 1.03–1.38 | 1.15 | 0.99–1.34 |
65–69 | 1777 | 20.3 | 1169 | 65.8 | 1.22 | 1.06–1.40 | 1.21 | 1.05–1.40 |
70–74 | 1625 | 18.5 | 995 | 61.2 | 1.00 | 1.00 | ||
75–79 | 1147 | 13.1 | 645 | 56.2 | 0.81 | 0.70–0.95 | 0.83 | 0.71–0.98 |
80–84 | 496 | 5.7 | 244 | 49.2 | 0.61 | 0.50–0.75 | 0.63 | 0.52–0.78 |
⩾85 | 102 | 1.2 | 56 | 54.9 | 0.77 | 0.52–1.15 | 0.80 | 0.53–1.21 |
Townsend quintile (socio-economic status) | ||||||||
1 (Least deprived) | 1241 | 14.2 | 801 | 64.5 | 1.00 | 1.00 | ||
2 | 1590 | 18.1 | 1032 | 64.9 | 1.02 | 0.87–1.19 | 0.99 | 0.84–1.16 |
3 | 1743 | 19.9 | 1102 | 63.2 | 0.94 | 0.81–1.10 | 0.93 | 0.80–1.09 |
4 | 1932 | 22.0 | 1213 | 62.8 | 0.93 | 0.80–1.08 | 0.90 | 0.77–1.05 |
5 (Most deprived) | 2152 | 24.5 | 1348 | 62.6 | 0.92 | 0.80–1.07 | 0.89 | 0.76–1.04 |
Missing | 110 | 1.3 | 44 | 40.0 | 0.37 | 0.25–0.55 | 0.37 | 0.25–0.56 |
Performance status | ||||||||
0 | 1626 | 18.5 | 1243 | 76.4 | 1.00 | 1.00 | ||
1 | 3208 | 36.6 | 2168 | 67.6 | 0.64 | 0.56–0.74 | 0.71 | 0.62–0.82 |
2 | 1664 | 19.0 | 903 | 54.3 | 0.37 | 0.31–0.42 | 0.45 | 0.38–0.52 |
3 | 683 | 7.8 | 279 | 40.8 | 0.21 | 0.18–0.26 | 0.27 | 0.22–0.33 |
4 | 53 | 0.6 | 20 | 37.7 | 0.19 | 0.11–0.33 | 0.23 | 0.13–0.41 |
Missing | 1534 | 17.5 | 927 | 60.4 | 0.47 | 0.40–0.55 | 0.56 | 0.48–0.66 |
Charlson co-morbidity index | ||||||||
0 | 3318 | 37.8 | 2298 | 69.3 | 1.00 | 1.00 | ||
1 | 1641 | 18.7 | 1076 | 65.6 | 0.85 | 0.75–0.96 | 0.93 | 0.81–1.05 |
2-3 | 1092 | 12.5 | 669 | 61.3 | 0.70 | 0.61–0.81 | 0.81 | 0.70–0.94 |
>3 | 2717 | 31.0 | 1497 | 55.1 | 0.54 | 0.49–0.61 | 0.69 | 0.62–0.77 |
Stage | ||||||||
Extensive | 4550 | 51.9 | 2712 | 59.6 | 1.00 | 1.00 | ||
Limited | 2646 | 30.2 | 1889 | 71.4 | 1.69 | 1.53–1.87 | 1.44 | 1.29–1.61 |
Missing | 1572 | 17.9 | 939 | 59.7 | 1.01 | 0.89–1.13 | 0.95 | 0.84–1.08 |
Time to treatment | ||||||||
<18 days | 4305 | 49.1 | 2773 | 64.4 | 1.00 | 1.00 | ||
⩾18 days | 4463 | 50.9 | 2767 | 62.0 | 0.90 | 0.83–0.98 | 0.81 | 0.74–0.89 |
Route of referral | ||||||||
Emergency admission | 1157 | 13.2 | 626 | 54.1 | 0.56 | 0.49–0.64 | 0.68 | 0.59–0.78 |
General Practitioner | 4666 | 53.2 | 3166 | 67.9 | 1.00 | 1.00 | ||
Consultant referral | 1556 | 17.7 | 950 | 61.1 | 0.74 | 0.66–0.84 | 0.85 | 0.75–0.97 |
Other (inc private) | 464 | 5.3 | 282 | 60.8 | 0.73 | 0.60–0.89 | 0.80 | 0.66–0.98 |
Emergency Department | 514 | 5.9 | 269 | 52.3 | 0.52 | 0.43–0.63 | 0.63 | 0.52–0.77 |
Missing | 411 | 4.7 | 247 | 60.1 | 0.71 | 0.58–0.88 | 0.82 | 0.66–1.01 |
Trust first seen | ||||||||
Non-chemotherapy trust | 2064 | 23.5 | 1260 | 61.0 | 1.00 | 1.00 | ||
Chemotherapy trust | 6688 | 76.3 | 4271 | 63.9 | 1.13 | 1.02–1.25 | 1.14 | 1.03–1.27 |
Missing/trust which saw <20 cases | 16 | 0.2 | 9 | 56.3 | 0.82 | 0.30–2.21 | 0.63 | 0.23–1.72 |
Radiotherapy | ||||||||
No chemo-radiotherapy | 7978 | 91.0 | 4919 | 61.7 | 1.00 | 1.00 | ||
Chemo-radiotherapy | 790 | 9.0 | 621 | 78.6 | 2.29 | 1.92–2.72 | 1.74 | 1.44–2.09 |
